Portal de Periódicos da CAPES

Pregnancy outcomes following gabapentin use

2013; Lippincott Williams & Wilkins; Volume: 80; Issue: 17 Linguagem: Inglês

10.1212/wnl.0b013e31828f18c1

1526-632X

Hisaki Fujii, Akash Goel, Nathalie Bernard, Alessandra Pistelli, Laura Yates, Sally Stephens, Jung Yeol Han, Doreen Matsui, Fatwa Etwell, Thomas R. Einarson, Gideon Koren, Adrienne Einarson,

Maternal Mental Health During Pregnancy and Postpartum

Objectives: Our objectives were to 1) determine whether first-trimester use of gabapentin is associated with an increased risk for major malformations; 2) examine rates of spontaneous abortions, therapeutic abortions, stillbirths, mean birth weight and gestational age at delivery; and 3) examine rates of poor neonatal adaptation syndrome following late pregnancy exposure. Methods: The study design was prospective. Women were included who initially contacted the services between 5 and 8 weeks with a comparison group of women exposed to nonteratogens, collected in a similar manner. Results: We have data on 223 pregnancy outcomes exposed to gabapentin and 223 unexposed pregnancies. The rates of major malformations were similar in both groups ( p = 0.845). There was a higher rate of preterm births ( p = 0.019) and low birth weight <2,500 g ( p = 0.033) in the gabapentin group. Among infants who were exposed to gabapentin up until delivery, 23 of 61 (38%) were admitted to either the neonatal intensive care unit or special care nursery for observation and/or treatment, vs 6 of 201 (2.9%) live births in the comparison group ( p < 0.001). There were 2 cases of possible poor neonatal adaptation syndrome in neonates exposed to gabapentin close to delivery, compared with none in the comparison group, although it must be noted that these infants were concomitantly exposed to other psychotropic drugs. Among the women who took gabapentin, the major indications were pain (n = 90; 43%) and epilepsy (n = 71; 34%); the remainder were for other indications, mostly psychiatric. Conclusion: Our results suggest that although this sample size is not large enough to make any definitive conclusions, and there was no comparator group treated with other antiepileptic drugs, gabapentin use in pregnancy does not appear to increase the risk for major malformations. This finding and the increased risk for low birth weight and preterm birth require further investigation.